Literature DB >> 21673229

Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy--conventional MR volumetry versus diffusion-weighted MR imaging.

Luís Curvo-Semedo1, Doenja M J Lambregts, Monique Maas, Thomas Thywissen, Rana T Mehsen, Guido Lammering, Geerard L Beets, Filipe Caseiro-Alves, Regina G H Beets-Tan.   

Abstract

PURPOSE: To determine diagnostic performance of diffusion-weighted (DW) magnetic resonance (MR) imaging for assessment of complete tumor response (CR) after combined radiation therapy with chemotherapy (CRT) in patients with locally advanced rectal cancer (LARC) by means of volumetric signal intensity measurements and apparent diffusion coefficient (ADC) measurements and to compare the performance of DW imaging with that of T2-weighted MR volumetry.
MATERIALS AND METHODS: A retrospective analysis of 50 patients with LARC, for whom clinical and imaging data were retrieved from a previous imaging study approved by the local institutional ethical committee and for which all patients provided informed consent, was conducted. Patients underwent pre- and post-CRT standard T2-weighted MR and DW MR. Two independent readers placed free-hand regions of interest (ROIs) in each tumor-containing section on both data sets to determine pre- and post-CRT tumor volumes and tumor volume reduction rates (volume). ROIs were copied to an ADC map to calculate tumor ADCs. Histopathologic findings were the standard of reference. Receiver operating characteristic (ROC) curves were generated to compare performance of T2-weighted and DW MR volumetry and ADC. The intraclass correlation coefficient (ICC) was used to evaluate interobserver variability and the correlation between T2-weighted and DW MR volumetry.
RESULTS: Areas under the ROC curve (AUCs) for identification of a CR that was based on pre-CRT volume, post-CRT volume, and volume, respectively, were 0.57, 0.70, and 0.84 for T2-weighted MR versus 0.63, 0.93, and 0.92 for DW MR volumetry (P = .15, .02, .42). Pre- and post-CRT ADC and ADC AUCs were 0.55, 0.54, and 0.51, respectively. Interobserver agreement was excellent for all pre-CRT measurements (ICC, 0.91-0.96) versus good (ICC, 0.61-0.79) for post-CRT measurements. ICC between T2-weighted and DW MR volumetry was excellent (0.97) for pre-CRT measurements versus fair (0.25) for post-CRT measurements.
CONCLUSION: Post-CRT DW MR volumetry provided high diagnostic performance in assessing CR and was significantly more accurate than T2-weighted MR volumetry. Post-CRT DW MR was equally as accurate as volume measurements of both T2-weighted and DW MR. Pre-CRT volumetry and ADC were not reliable.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21673229     DOI: 10.1148/radiol.11102467

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  88 in total

Review 1.  [The role of cross-sectional imaging in staging of rectal cancer].

Authors:  A O Schäfer; M Langer; T Baumann
Journal:  Chirurg       Date:  2012-05       Impact factor: 0.955

Review 2.  Functional MRI for radiotherapy dose painting.

Authors:  Uulke A van der Heide; Antonetta C Houweling; Greetje Groenendaal; Regina G H Beets-Tan; Philippe Lambin
Journal:  Magn Reson Imaging       Date:  2012-07-06       Impact factor: 2.546

3.  Diffusion-weighted magnetic resonance imaging for prediction of tumor response to neoadjuvant chemoradiotherapy using irinotecan plus S-1 for rectal cancer.

Authors:  Hiroshi Doi; Naohito Beppu; Takashi Kato; Masashi Noda; Hidenori Yanagi; Naohiro Tomita; Norihiko Kamikonya; Shozo Hirota
Journal:  Mol Clin Oncol       Date:  2015-07-21

4.  T2-weighted signal intensity-selected volumetry for prediction of pathological complete response after preoperative chemoradiotherapy in locally advanced rectal cancer.

Authors:  Sungwon Kim; Kyunghwa Han; Nieun Seo; Hye Jin Kim; Myeong-Jin Kim; Woong Sub Koom; Joong Bae Ahn; Joon Seok Lim
Journal:  Eur Radiol       Date:  2018-06-01       Impact factor: 5.315

5.  Intravoxel Incoherent Motion-derived Histogram Metrics for Assessment of Response after Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison between Single-Section and Volumetric Analyses.

Authors:  Stephanie Nougaret; Hebert Alberto Vargas; Yulia Lakhman; Romain Sudre; Richard K G Do; Frederic Bibeau; David Azria; Eric Assenat; Nicolas Molinari; Marie-Ange Pierredon; Philippe Rouanet; Boris Guiu
Journal:  Radiology       Date:  2016-02-26       Impact factor: 11.105

6.  The value of diffusion kurtosis magnetic resonance imaging for assessing treatment response of neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Authors:  Jing Yu; Qing Xu; Jia-Cheng Song; Yan Li; Xin Dai; Dong-Ya Huang; Ling Zhang; Yang Li; Hai-Bin Shi
Journal:  Eur Radiol       Date:  2016-09-08       Impact factor: 5.315

Review 7.  Management of the Complete Clinical Response.

Authors:  Angelita Habr-Gama; Guilherme Pagin São Julião; Bruna Borba Vailati; Ivana Castro; Debora Raffaele
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

8.  Volume Measurement by Diffusion-Weighted Imaging in Cervical Cancer.

Authors:  Shinya Fujii; Naoki Iwata; Chie Inoue; Naoko Mukuda; Takeru Fukunaga; Toshihide Ogawa
Journal:  Yonago Acta Med       Date:  2017-06-26       Impact factor: 1.641

9.  Development and validation of an MRI-based model to predict response to chemoradiotherapy for rectal cancer.

Authors:  Philippe Bulens; Alice Couwenberg; Karin Haustermans; Annelies Debucquoy; Vincent Vandecaveye; Marielle Philippens; Mu Zhou; Olivier Gevaert; Martijn Intven
Journal:  Radiother Oncol       Date:  2018-01-31       Impact factor: 6.280

10.  Machine learning for prediction of chemoradiation therapy response in rectal cancer using pre-treatment and mid-radiation multi-parametric MRI.

Authors:  Liming Shi; Yang Zhang; Ke Nie; Xiaonan Sun; Tianye Niu; Ning Yue; Tiffany Kwong; Peter Chang; Daniel Chow; Jeon-Hor Chen; Min-Ying Su
Journal:  Magn Reson Imaging       Date:  2019-05-03       Impact factor: 2.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.